Exelixis

Why Merck's Latest Success Means Trouble for Exelixis Inc.
Why Merck's Latest Success Means Trouble for Exelixis Inc.
Yahoo/Motley Fool
Merck
Exelixis
Cabometyx
Keytruda
Flag link:
Exelixis Begins Ph III Trial of Cabometyx in Refractory Thyroid Cancer
Exelixis Begins Ph III Trial of Cabometyx in Refractory Thyroid Cancer
CP Wire
Exelixis
Cabometyx
thyroid cancer
Flag link:
Exelixis Begins Ph III Trial of Cabometyx in Refractory Thyroid Cancer
Exelixis
Cabometyx
thyroid cancer
Flag link:
Exelixis and Ipsen Announce Positive CHMP Opinion for Cabometyx in Previously Treated Hepatocellular Carcinoma
Exelixis and Ipsen Announce Positive CHMP Opinion for Cabometyx in Previously Treated Hepatocellular Carcinoma
CP WIre
Exelixis
Ipsen
Cabometyx
hepatocellular carcinoma
Flag link:
Exelixis and Ipsen Announce Positive CHMP Opinion for Cabometyx in Previously Treated Hepatocellular Carcinoma
Exelixis
Ipsen
Cabometyx
hepatocellular carcinoma
Flag link:
Canada Approves Cabometyx for Adults with Previously Treated Advanced Renal Cell Carcinoma
Canada Approves Cabometyx for Adults with Previously Treated Advanced Renal Cell Carcinoma
CP Wire
Exelixis
Cabometyx
Takeda
Canada
Japan
Ipsen
renal cell carcinoma
Flag link:
Canada Approves Cabometyx for Adults with Previously Treated Advanced Renal Cell Carcinoma
Exelixis
Ipsen
Cabometyx
Flag link:
National Comprehensive Cancer Network Releases New Guidelines for Cabometyx for Advanced Renal Cell Carcinoma
National Comprehensive Cancer Network Releases New Guidelines for Cabometyx for Advanced Renal Cell Carcinoma
CP Wire
Exelixis
Cabometyx
advanced renal cell carcinoma
Flag link:
National Comprehensive Cancer Network Releases New Guidelines for Cabometyx for Advanced Renal Cell Carcinoma
Exelixis
Cabometyx
advanced renal cell carcinoma
Flag link:
Exelixis Gets the Patients Eventually
Exelixis Gets the Patients Eventually
Motley Fool
Exelixis
kidney cancer
renal cell carcinoma
Cabometyx
Flag link:
Exelixis Expands Ph Ib Immunotherapy Trial to Include Additional Patients with Locally Advanced or Metastatic Solid Tumors
Exelixis Expands Ph Ib Immunotherapy Trial to Include Additional Patients with Locally Advanced or Metastatic Solid Tumors
CP Wire
Exelixis
clinical trials
Cabometyx
Tecentriq
Flag link:
Exelixis Expands Ph Ib Immunotherapy Trial to Include Additional Patients with Locally Advanced or Metastatic Solid Tumors
Exelixis
Cabometyx
Tecentriq
Flag link:
The Week Ahead In Biotech: ASCO Presentations In The Spotlight
The Week Ahead In Biotech: ASCO Presentations In The Spotlight
Yahoo/Benzinga
ASCO 2018
European Society of Cardiology
TherapeuticsMD
Abiomed
Incyte
Bluebird Bio
Celgene
Syndax
Loxo Oncology
Exelixis
Karyopharm
Endocyte
Celldex Therapeutics
Jounce Therapeutics
Bristol-Myers Squibb
Nektar
Flag link:
Exelixis and Ipsen Announce European Approval of Cabometyx for Previously Untreated Intermediate- or Poor-Risk Advanced Renal Cell Carcinoma
Exelixis
Ipsen
Cabometyx
advanced renal cell carcinoma
renal cell carcinoma
Flag link:
Roche Tecentriq and Cotellic Combination Fails Ph III Trial in Colorectal Cancer
Roche Tecentriq and Cotellic Combination Fails Ph III Trial in Colorectal Cancer
CP Wire
Roche
Exelixis
Tecentriq
Cotellic
colorectal cancer
Flag link:
Roche Tecentriq and Cotellic Combination Fails Ph III Trial in Colorectal Cancer
Roche
Exelixis
Tecentriq
Cotellic
Flag link:
Exelixis and Invenra Partner to Develop Novel Biologics for Cancer Treatment
Exelixis and Invenra Partner to Develop Novel Biologics for Cancer Treatment
CP Wire
Exelixis
Invenra
cancer
Merck
drug development
Flag link:
Exelixis and Invenra Partner to Develop Novel Biologics for Cancer Treatment
Exelixis
Invenra
Flag link:
Roche halts enrollment in a PhII combo study of Tecentriq and Cotellic in wake of several patient deaths
Roche halts enrollment in a PhII combo study of Tecentriq and Cotellic in wake of several patient deaths
Endpoints
Roche
Tecentriq
clinical trials
colon cancer
Exelixis
Cotellic
Flag link:
The Secret Sauce Behind Exelixis, Inc.'s 12% Move Higher in December
The Secret Sauce Behind Exelixis, Inc.'s 12% Move Higher in December
Motley Fool
Exelixis
Cabometyx
renal cell carcinoma
Flag link:

Pages